NeuroSense Secures $500,000 Private Placement at 40% Premium to Market Price

Strategic Insights -

NeuroSense, a late-clinical stage biotechnology company, has announced a definitive agreement with a single investor for a $500,000 private placement of ordinary shares. The agreement calls for the issuance of 333,334 ordinary shares at a purchase price of $1.50 per share, representing a 40% premium to the closing price of the Company's ordinary shares on September 3, 2025. The private placement is expected to close on September 8, 2025, subject to customary conditions. Proceeds from the financing will be used for general corporate purposes and working capital.

Key Takeaways:

  • NeuroSense has entered into a definitive agreement with a single investor for a $500,000 private placement of ordinary shares at a premium of 40% to market price.
  • The private placement will result in the issuance of 333,334 ordinary shares at a purchase price of $1.50 per share, as of September 3, 2025.
  • Proceeds from the financing will be used for general corporate purposes and working capital, rather than towards specific R&D expenses or operations.
  • This is NeuroSense's third financing with private investors at a premium to market, which allows the company to strengthen its balance sheet while minimizing dilution for shareholders.
  • The offering is being made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act and/or Regulation D thereunder.
  • The securities offered and sold in this transaction have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Statistics:

  • $500,000: The amount of the private placement of ordinary shares.
  • $1.50: The purchase price per share, representing a 40% premium to closing price on September 3, 2025.
  • 333,334: The number of ordinary shares to be issued under the agreement.
  • 40%: The premium to market price at which the ordinary shares will be issued.
  • 3: The number of NeuroSense's financing agreements with private investors at a premium to market.

Sources:

  • (NASDAQ: NRSN) - the original press release announcing the private placement agreement.
  • "Forward-Looking Statements" section of the original press release, which outlines potential risks and uncertainties associated with the offering.